MORF News and Press, Morphic Holding Inc. From 10/24/22

WALTHAM, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the completion of targeted enrollment of 30 patients ah...

200 mg BID dose demonstrates receptor saturation and statistically significant increases in key circulating T lymphocyte populations Lymphocyte changes consistent with approved α4β7 inhibitor WALTHAM, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Morphic The...

Recognized for pioneering work in field of integrin receptor biology, leading to new treatments for multiple autoimmune disorders Founder, Director, and Scientific Advisory Board member of Morphic Therapeutic WALTHAM, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Morphic The...

Paper describes key insight into integrin conformation, overcoming critical drug development challenge Company lauds Tim Springer, PhD, scientific founder of Morphic and Fu-Yang “Albert” Lin, PhD, first company employee WALTHAM, Mass., Sept. 21, 2022 (GLOBE N...

WALTHAM, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will participate i...

Morphic press release ( NASDAQ: MORF ): Q2 GAAP EPS of -$0.68 beats by $0.17 . Revenue of $60.2M (+1463.6% Y/Y). As of June 30, 2022, Morphic had cash, cash equivalents and marketable securities of $397.6 million, compared to $380.7 million as of March 31, 2022. ...

Continued enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis Announced key appointments and advancements in leadership team Ended second quarter 2022 with $397.6 million in cash and equivalents Cash runway extended into second ...

For further details see: Morphic coverage initiated with Outperform by SVB Securities

Clinical-stage biotech Morphic Holding (NASDAQ:MORF) announced that AbbVie (ABBV) has decided to terminate the collaboration and option agreement the pharma giant inked with its subsidiary Morphic Therapeutic in 2018 for integrin therapeutics. Integrins are a class of receptors that use both ...

Gainers: Novavax (NVAX) +259%. Precision BioSciences (DTIL) +114%. Amazon.com (AMZN) +39%. Adobe (ADBE) +32%. Paratek Pharmaceuticals (PRTK) +15%. Losers:Euronet Worldwide (EEFT) -5%. Seres Therapeutics (MCRB) -5%. Sanderson Farms (SAFM) -5%. Morphic Holding (MORF) -4%. Redbox Entertainm...